2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Julie M. Vose, MD, MBA, discusses the durability of response to epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
"For this heavily treated patient population, I think that's a really high overall response rate."
Julie M. Vose, MD, MBA, professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discussed 3-year outcomes from a post hoc analysis of the phase 1/2 EPCORE NHL-1 trial (NCT03625037), evaluating the durability of response to epcoritamab-bysp (Epkinly) monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who achieved a complete response (CR) at 2 years.
Epcoritamab, a subcutaneous bispecific antibody targeting CD3 and CD20, was evaluated in a heavily pretreated R/R LBCL population, including patients ineligible for autologous stem cell transplant or CAR T-cell therapy. In the pivotal cohort, the overall response rate was 41% (n = 65/157), and 32 patients had a CR at 2 years.
At 3 years, 96% of these patients who had a CR at 2 years remained free from progression, and the overall survival (OS) rate at 3 years was 97% for this group. According to Vose, this subset analysis represents an important contribution to understanding the potential for prolonged disease control in a population with limited treatment options.
The findings underscore the potential of epcoritamab to induce deep and lasting remissions, particularly for patients achieving a CR early in the course of treatment, she said. Although the agent is currently used in later-line settings, the durability data may inform future strategies regarding optimal sequencing or consolidation.
Vose noted that although the data are compelling, long-term follow-up and confirmatory studies remain necessary to evaluate OS and long-term safety. Additionally, ongoing investigations may help identify predictive markers for sustained response and guide patient selection.
Related Content: